Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Norethisterone enantate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Noristerat is an injectable (depot) contraceptive. It is intended as a short-term method of contraception, for example in women whose partners are undergoing vasectomy, until the vasectomy is effective. It is also for use in women immunised against rubella, to prevent pregnancy while the virus is active. You use it to stop you getting pregnant. Noristerat contains a type of female sex hormone, called a progestogen. This hormone stops you getting pregnant by working in three ways: by preventing an egg being released from your ovaries; by making the fluid (mucus) in your cervix thicker, which makes it more difficult for sperm to enter the womb; and by preventing the lining of your womb thickening enough for an egg to grow in it. The benefits of using Noristerat include: it is one of the most reliable reversible methods of contraception if used correctly you only have to remember to visit your doctor after 8 weeks for a second injection it doesn't interrupt sex Noristerat will not protect you against sexually transmitted infections, such as Chlamydia or HIV. Only condoms can help to do this.
2.
Make sure Noristerat is OK for you
It's important that you understand the benefits and risks of using Noristerat before you are given it, or when deciding whether to have a second injection. Although Noristerat is suitable for most healthy women it isn't suitable for everyone. ➜ Tell your doctor if you have any of the illnesses or risk factors mentioned in this leaflet. Before you are given Noristerat Your doctor will ask about you and your family's medical problems, check your blood pressure and exclude the likelihood of you being pregnant. You may also need other checks, such as a breast examination, but only if these examinations are necessary for you, or if you have any special concerns. While you're on Noristerat Check your breasts and nipples every month for changes – tell your doctor if you can see or feel anything odd, such as lumps or dimpling of the skin. If you need a blood test or other laboratory tests, tell your doctor or the laboratory staff that you are using Noristerat, because hormonal contraceptives can affect the results of some tests.
v014
Page 2 of 9
2.1
If you're going to have an operation, make sure your doctor knows about it. You may need to avoid having a second injection of Noristerat before the operation. This is to reduce the risk of a blood clot (see section 2.1). Noristerat and blood clots
Noristerat may slightly increase your risk of having a blood clot (called a thrombosis), especially in the first year of using it. A clot in a leg vein – a deep vein thrombosis (or DVT) – is not always serious. However, if it moves up the veins and blocks an artery in the lungs, it can cause chest pain, breathlessness, collapse or even death. This is called a pulmonary embolism and is very rare. Very rarely, blood clots can also form in the blood vessels of the heart (causing a heart attack) or the brain (causing a stroke). In healthy young women the chance of having a heart attack or stroke is extremely small. You are more at risk of having a blood clot: as you get older if you smoke if you are seriously overweight if you have some diseases of the heart and blood vessels if you suffer from migraines if you have recently had a baby if you're off your feet for a long time because of major surgery, injury or illness ➜ Tell your doctor if any of these risk factors apply to you. Noristerat may not be suitable for you. Signs of a blood clot include:
a migraine for the first time, a migraine that is worse than normal or unusually frequent or severe headaches any sudden changes to your eyesight (such as loss of vision or blurred vision) any sudden changes to your hearing, speech, sense of smell, taste or touch pain or swelling in your leg stabbing pain when you breathe coughing for no apparent reason pain and tightness in the chest sudden weakness or numbness in one side or part of your body dizziness or fainting.
➜ See a doctor as soon as possible. Do not have a further injection until your doctor says you can. Use another method of contraception, such as condoms, in the meantime. v014
Page 3 of 9
2.2
Noristerat and cancer
Noristerat has also been linked to liver diseases, such as jaundice and non-cancer liver tumours, but this is rare. Very rarely, Noristerat has also been linked with some forms of liver cancer in women who have used it for a long time. ➜ See a doctor as soon as possible if you get severe pain in your stomach, or yellow skin or eyes (jaundice). You may need to stop using Noristerat . 2.3
Noristerat should not be used by some women
➜ Tell your doctor or family planning nurse if you have any medical problems or illnesses. Do not use Noristerat if you have any of the problems listed below. Using Noristerat would put your health at risk.
If you are pregnant or might be pregnant If you have ever had a problem with your blood circulation. This includes a blood clot (thrombosis) in the legs (deep vein thrombosis), lungs (pulmonary embolism), heart (heart attack), brain (stroke) or any other parts of the body If you have or have ever had severe liver disease, and you have been told by your doctor that your liver function test results are not yet back to normal If you have or have ever had liver tumours If you have severe diabetes affecting your blood vessels If you have very high blood pressure If you have disorders of blood fat (lipid) metabolism If you have or suspect you have cancer affected by sex hormones – such as some cancers of the breast or womb lining or have ever had either of these conditions If you have an inherited disease called porphyria If you are allergic (hypersensitive) to norethisterone enantate or any of the other ingredients in Noristerat (listed in section 6).
➜ If you suffer from any of these, or get them for the first time while using Noristerat, contact your doctor as soon as possible. It may not be suitable for you to have a second injection of Noristerat. 2.4
Noristerat can make some illnesses worse
Some of the conditions listed below can be made worse by using Noristerat. Or they may mean it is less suitable for you. You may still be able to be given Noristerat but you need to take special care. If you have had severe depression If you have ever had liver problems, e.g. jaundice (yellow skin or eyes) If you have any disease that tends to get worse during pregnancy If you have an irregular menstrual pattern together with stomach pains If you have abnormal vaginal bleeding If you have diabetes v014
Page 4 of 9
If you have ever had an ectopic pregnancy or fallopian tube removed.
The main ingredient of Noristerat (the progestogen, norethisterone enantate) is partly converted into the oestrogen, ethinylestradiol. The expected concentration of ethinylestradiol in your body is relatively low compared to taking combined hormonal contraceptives containing ethinylestradiol. This means that although effects similar to those after taking combined hormonal contraceptives containing ethinylestradiol cannot be completely ruled out, experience to date suggests that this may not be the case. ➜ Tell your doctor or family planning nurse if any apply to you. Also tell them if you get any of these for the first time after being given Noristerat, or if any get worse or come back, because it may not be suitable for you to have a second injection of Noristerat. 2.5
Psychiatric disorders
Some women using hormonal contraceptives including Noristerat have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible.
2.6
Taking other medicines
If you ever need to take another medicine or herbal products at the same time, always tell your doctor, pharmacist or dentist that you've been given Noristerat. Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives. Some medicines can stop Noristerat from working properly – for example: certain sedatives (called barbiturates) some medicines used to treat epilepsy some medicines used to treat HIV and Hepatitis C virus infections (socalled protease inhibitors and non-nucleoside reverse transcriptase inhibitors) griseofulvin (an anti-fungal medicine) phenylbutazone (an anti-inflammatory medicine) certain antibiotics St. John's Wort (a herbal remedy). If you do need to take one of these medicines, you may need to use extra contraception (for example condoms) for a while. Your doctor, pharmacist or dentist can tell you if this is necessary and for how long. Noristerat can also affect how well other medicines work. For example, if you have diabetes, you may need to take more insulin or other anti-diabetic drugs after being given Noristerat. Your doctor will tell you if this is necessary.
v014
Page 5 of 9
2.7
Using Noristerat with food and drink
There are no special instructions about food and drink while on Noristerat 2.8
Pregnancy and breast-feeding
Pregnancy You should not be given Noristerat if you are pregnant. If you think you might be pregnant, do a pregnancy test to confirm that you are and do not have your second injection. Breast-feeding Noristerat has not been shown to reduce the amount of milk you produce which is an advantage if you wish to breastfeed your baby. Very small amounts of the hormone are found in breast milk. There is no evidence to suggest that the small amounts of the hormone that appear in the milk are harmful to a healthy baby. However, if your baby has severe or long-lasting jaundice that requires medical treatment you should not breast-feed your baby after having your injection. 2.9
Driving and using machines
Noristerat has no known effect on the ability to drive or use machines. 2.10
Noristerat contains benzyl benzoate
This medicine contains 333.8 mg benzyl benzoate in each 1 ml ampoule. Benzyl benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
3.
Noristerat
3.1
How to start
Your doctor or family planning clinic will give you the first injection of Noristerat within the first five days of your period (unless you start just after a pregnancy or an abortion). The injection is given into the muscle. By starting in this way you will have contraceptive protection at once. 3.2
Further injections of Noristerat
One injection will give you contraception for 8 weeks. After 8 weeks a second injection can be given. You must make sure that you leave no longer than 8 weeks between injections or contraceptive protection will be lost.
v014
Page 6 of 9
3.3
Starting Noristerat after having a baby
Noristerat can normally be used straight after having a baby. Your doctor will advise you on when to start. 3.4
Starting Noristerat after having a miscarriage or an abortion
You may be able to have an injection immediately. Your doctor will advise you. 3.5
Missed a period – could you be pregnant?
If, when the second injection is due, you have not had a further period since the first injection, it is unlikely that you are pregnant, but the second injection should not be given until pregnancy has been ruled out. 3.6
Being given more Noristerat than you should
Overdosage is unlikely but if it does occur no serious ill-effects are expected.
4.
Possible side effects
Like all medicines, Noristerat can cause side effects, although not everybody gets them. ➜ Tell your doctor, pharmacist or family planning nurse if you are worried about any side effects which you think may be due to Noristerat. 4.1
Serious side effects – see a doctor straight away
Signs of a blood clot: a migraine for the first time, a migraine that is worse than normal or unusually frequent or severe headaches any sudden changes to your eyesight (such as loss of vision or blurred vision) any sudden changes to your hearing, speech, sense of smell, taste or touch pain or swelling in your leg stabbing pain when you breathe coughing for no apparent reason pain and tightness in the chest sudden weakness or numbness in one side or part of your body dizziness or fainting. Signs of a severe allergic reaction to Noristerat: swelling of the face, lips, mouth, tongue or throat. Signs of severe liver problems include: severe pain in your upper abdomen yellow skin or eyes (jaundice) inflammation of the liver (hepatitis) v014
Page 7 of 9
your whole body starts itching.
➜ If you think you may have any of these, see a doctor straight away. You may need to stop using Noristerat. 4.2
Less serious side effects
irregular bleeding bloating tender breasts headaches depressive moods dizziness feeling sick putting on weight skin reactions (e.g. pain or itchy rash) at the injection site rarely coughing for no apparent reason, shortness of breath and disturbances of the circulatory system may develop while you are having your injection, or immediately after.
➜ Tell your doctor or family planning nurse if you are worried about any side effects which you think may be due to Noristerat. Also tell them if any existing conditions get worse while you are using Noristerat. Reporting of side effects If you get any side effects, talk to your doctor, family planning nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report
directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5.
Noristerat
Keep this medicine out of the sight and reach of children. Noristerat should not be used after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month. Store below 25C. Protect from light.
6.
What is in Noristerat and who makes it
What is in Noristerat The active substance is norethisterone enantate.
v014
Page 8 of 9
Each ampoule of Noristerat contains 200mg of the progestogen norethisterone enantate in 1ml of oily solution for injection into a muscle. The other ingredients are benzyl benzoate and castor oil for injection. What Noristerat looks like and contents of the pack Noristerat is a solution for intramuscular injection; the injection is given into the muscle. Noristerat is supplied in single packs of 1 ampoule. The company that holds the product licence for Noristerat is: Bayer plc, 400 South Oak Way, Reading, RG2 6AD Noristerat is made by: Bayer AG, Muellerstrasse 178, 13353 Berlin, Germany. This leaflet was last updated in June 2019.
v014
Page 9 of 9
Noristerat 200mg, solution for intramuscular injection comes as injection containing 200mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Noristerat 200mg, solution for intramuscular injection is norethisterone enantate.
This leaflet reproduces the patient information leaflet approved for Noristerat 200mg, solution for intramuscular injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Noristerat is a depot contraceptive. It is intended for short-term use when a high level of efficacy independent of possible errors by the patient is required. It has been licensed for short-term use by women whose partners undergo vasectomy, until the vasectomy is effective, and women immunised against rubella, to prevent pregnancy during the period of activity of the virus.
Use after delivery or abortion: Noristerat can generally be used immediately after delivery or abortion (but see Section 4.6 'Use during lactation').
200 mg Noristerat intramuscularly provides contraception for eight weeks. The first injection should be given within the first five days of a menstrual cycle (the first day of menstruation counting as day 1), unless it is given so soon after delivery or abortion that no possibility of pregnancy exists. Provided the injection is carried out according to these instructions, no additional contraceptive cover is required. The injection may be repeated once, after eight weeks. Noristerat must always be injected deep into the gluteal muscles, care being taken that no liquid runs back from the injection site, which could result in loss of efficacy. The viscosity of the liquid at low temperatures is high, necessitating considerable pressure of injection. Therefore it is suggested that the ampoule be immersed in warm water before injection. A needle of at least medium bore should be used, and care taken to ensure that the needle is securely attached to the syringe. The injection must be administered extremely slowly (see Section 4.4 Special Warnings and Precautions for use).
- Known or suspected pregnancy.
- Current or severe hepatic disease as long as liver function values have not returned to normal.
- Previous or existing liver tumours.
- Severe diabetes with vascular changes.
- Pathologically increased blood pressure.
- Current thromboembolic disease.
- Disturbances of lipid metabolism.
- Suspected, existing or treated breast or endometrial cancer.
- Porphyria
- Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Medical Examination
Assessment of women prior to starting Noristerat (and at regular intervals thereafter) should include a personal and family medical history of each woman. Physical examination should be guided by this and by the contraindications (section 4.3) and warnings (section 4.4) for this product. The frequency and nature of these assessments should be based upon relevant guidelines and should be adapted to the individual woman, but should include measurement of blood pressure and, if judged appropriate by the clinician, breast, abdominal and pelvic examination including cervical cytology.
Before starting treatment, pregnancy must be excluded.
Women should be advised that progestogen-only contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases.
Gynaecological considerations
Noristerat should not be used in patients with abnormal uterine bleeding until a definite diagnosis has been established and the possibility of genital tract malignancy eliminated. Undiagnosed vaginal bleeding that is suspicious for underlying conditions should be investigated prior to first injection and endometrial pathology should be excluded if it occurs in women over 40 after prolonged amenorrhoea.
If there is a history of ectopic pregnancy or one fallopian tube is missing, the use of Noristerat should be decided on only after carefully weighing the benefits against the risks.
If obscure lower abdominal complaints occur together with an irregular cycle pattern (above all amenorrhoea followed by persistent irregular bleeding), an extrauterine pregnancy must be considered.
The patient should be informed before starting Noristerat that her menstrual pattern is likely to alter during the entire exposure period. Menstrual changes in the form of spotting, breakthrough bleeding and delayed menstruation are relatively frequent, and generally do not require treatment.
Amenorrhoea: if, when the second injection is due, bleeding has not occurred in the preceding eight weeks the second injection should not be given until pregnancy has been ruled out.
Partial metabolization of norethisterone to ethinylestradiol
Norethisterone is partly metabolised to ethinylestradiol (EE) after intramuscular administration in humans. This conversion results in a systemic EE exposure corresponding to an oral equivalent dose of about 4 µg EE per day, on average, over 8 weeks. Mean oral equivalent doses per day are about 10 μg EE during the first 2 weeks after Noristerat administration and decline to about 5 μg EE in the 3rd week and about 2 μg EE from the 5th week onwards. Therefore, systemic estrogen effects cannot be excluded (see section 5.2). Post-marketing experience with Noristerat indicates that the safety profile of Noristerat does not resemble that of combined hormonal contraceptives.
Circulatory disorders:
There is a general opinion, based on statistical evidence, that users of hormonal contraceptives experience, more often than non-users, venous thromboembolism, arterial thrombosis, including cerebral and myocardial infarction, and subarachnoid haemorrhage. Full recovery from such disorders does not always occur, and it should be realised that in a few cases they are fatal.
The relative risk of arterial thrombosis (e.g. stroke and myocardial infarction) appears to increase further when heavy smoking, increasing age and the use of hormonal contraceptives coincide.
Although there have been so far no observations of thromboembolic disease during the use of Noristerat, as a precaution it is recommended that this preparation should not be used where there is a history of thromboembolic processes.
No further injection should be given if symptoms of an arterial or venous thrombotic event occur during treatment, e.g.
• new onset or exacerbation of migraine-type headaches,
• sudden disturbances of vision or hearing perceptual disorders occur,
• significant rise in blood pressure,
• first signs of thrombosis or blood clots.
Liver Function
Porphyria and existing impairment of liver function might theoretically be exacerbated by Noristerat.
In rare cases benign, and in even rarer cases malignant, liver tumours leading in isolated cases to life-threatening intra-abdominal haemorrhage, have been observed after the use of hormonal substances such as the one contained in Noristerat. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur, a liver tumour should be considered in the differential diagnosis.
Women with a history of disturbed liver function or any disease that is prone to worsen during pregnancy such as idiopathic jaundice or severe pruritus of pregnancy should be carefully observed during medication.
Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of Noristerat.
Other conditions
A reduction of glucose tolerance has been observed in some women using progestogens. Consequently, diabetics and women with a tendency to diabetes should be carefully supervised during the use of Noristerat. In the case of diabetes, it may be necessary to reassess the required doses of antidiabetics or insulin.
In rare cases coughing, dyspnoea and circulatory irregularities may occur during or immediately after the injection. Experience has shown that these reactions can be avoided by injecting Noristerat very slowly.
Women with a history of severe depressive states should be carefully observed during medication. No further injection should be given, if during treatment, recurrence of earlier depression is experienced.
Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.
Effect on blood chemistry: No influence of Noristerat on basal plasma cortisol, the ACTH test or the metyrapone test has been observed. In the acute dexamethasone suppression test, however, a higher plasma cortisol value than expected was found in 4 out of 10 women, although there were no clinical indications of disturbed adrenocortical function. A shortening of the recalcification time and of the thromboplastin time (Quick's test) were observed in studies of the blood coagulation system.
Information about excipients
This medicine contains 333.8 mg benzyl benzoate in each 1 ml ampoule.
Benzyl benzoate may increase jaundice in newborn babies (up to 4 weeks old).
Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.
There are no data on progestogen-only injectables drug interactions.
Effects of other medicinal products on Noristerat
Direct clinical evidence for reduced effectiveness of Noristerat has not been obtained. However, theoretical interactions based on findings with combined oral contraceptives include the following, which have been shown to have clinically important interactions:
Anticonvulsants: phenytoin, barbiturates, primidone, carbamazepine, phenylbutazone, oxcarbazepine, topiramate, felbamate.
Antifungal agents:griseofulvin.
Certain antibiotics: rifampicin and ampicillin (possibly due to changes in the intestinal flora).
Herbal remedies: products containing St John's wort (Hypericum perforatum).
Antiviral agents: HIV/HCV protease inhibitors and non-nucleoside reverse transcriptase inhibitors can have variable effects on the plasma concentrations of sex hormones.
Substances decreasing the clearance of sex hormones (enzyme inhibitors)
Strong and moderate CYP3A4 inhibitors such as azole antifungals (e.g. fluconazole, itraconazole, ketoconazole, voriconazole) and macrolides (e.g. erythromycin) can increase plasma concentrations of the progestin.
Effects of Noristerat on other medicinal products
Hormonal contraceptives may affect the metabolism of certain other drugs. Accordingly, plasma and tissue concentrations may be affected (e.g. increased ciclosporin plasma concentrations).
The requirement for oral antidiabetics or insulin can change as a result of the effect on glucose tolerance.
Other forms of interaction
Laboratory tests
The use of contraceptive steroids may influence the results of certain laboratory tests.
Pharmacodynamic interactions
Co-administration of ethinylestradiol-containing medicinal products with direct-acting antiviral (DAA) medicinal products containing ombitasvir, paritaprevir, or dasabuvir, and combinations of these has been shown to be associated with increases in ALT levels to greater than 20 times the upper limit of normal in healthy female subjects and HCV infected women. Since norethisterone is partly metabolised to ethinylestradiol after intramuscular Noristerat administration in humans (see section 5.2) such an interaction cannot be excluded.
Pregnancy
Noristerat is contraindicated in pregnancy.
Like all nortestosterone derivatives used for contraception, Noristerat has slight androgenic activity, and a virilising effect on the external genitalia of a female foetus exposed to Noristerat after the first month of pregnancy cannot be totally ruled out on theoretical grounds. However, no such virilisation has been observed after the few pregnancies that have been reported during the use of Noristerat.
Lactation
There appear to be no adverse effects on infant growth or development when using Noristerat after six weeks postpartum. Noristerat does not appear to affect the quantity or quality of breast milk, however, minute amounts of the active substance are excreted with the milk and although considered harmless to a healthy neonate, might theoretically, like other steroids, impair the degradation of bilirubin, especially during the first week of life. If the mother has received Noristerat, breast-feeding should therefore be withheld from neonates with severe or persistent jaundice requiring medical treatment.
None known.
Undesirable effects that have been reported in users of Noristerat (based on post-marketing data) are:
System Organ Class
Very common
≥ 1/10
Common
≥ 1/100 and < 1/10
Uncommon
≥ 1/1.000 and < 1/100
Immune system disorders
Hypersensitivity reaction
Metabolism and nutrition disorders
Weight increase
Psychiatric disorders
Depressed mood
Nervous system disorders
Dizziness
Headache
Gastrointestinal disorders
Nausea
Skin and subcutaneous tissue disorders
Skin disorder
Reproductive system and breast disorders
Uterine / Vaginal bleeding including Spotting
Amenorrhoea (short lasting)
breast discomfort
General disorders and administration site conditions
Injection site reaction
Local skin reaction
Bloating
Administration-related events:
Experience has shown that the short-lasting reactions (urge to cough, paroxysmal cough, respiratory distress, dyspnoea and circulatory irregularities) may occur in isolated cases during or immediately after the injection of oily solutions if the solution is injected too rapidly (see Section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Presentation of a single use injectable and administration by a physician minimize the risk of overdose. There have been no reports of serious deleterious effects from overdose. There are no antidotes and further treatment should be symptomatic.
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Norethisterone enantate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Noristerat 200mg, solution for intramuscular injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.